QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.062836v1 310/2/620    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by De Vry, J. Articles by Mauler, F. Search for Related Content PubMed PubMed Citation Articles by De Vry, J. Articles by Mauler, F.

NEUROPHARMACOLOGY

3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB₁/CB₂ Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects

Central Nervous System Research (J.D.V., D.D., M.E., E.R., F.M.) and Medicinal Chemistry (M.H., H.M.), Bayer HealthCare, Wuppertal, Germany

3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074) is a novel, selective cannabinoid CB₁/CB₂ receptor ligand (K_i = 55.4, 48.3, and 45.5 nM at rat and human cannabinoid CB₁ and human CB₂ receptors, respectively), with partial agonist properties at these receptors in guanosine 5-[³⁵S]-thiophosphate triethyl-ammonium salt ([³⁵S]GTPS) binding assays. In rats, generalization of BAY 59-3074 to the cue induced by the cannabinoid CB₁ receptor agonist (–)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 38-7271) in a drug discrimination procedure, as well as its hypothermic and analgesic effects in a hot plate assay, were blocked by the cannabinoid CB₁ receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR 141716A). BAY 59-3074 (0.3–3 mg/kg, p.o.) induced antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic (chronic constriction injury, spared nerve injury, tibial nerve injury, and spinal nerve ligation models) and inflammatory pain (carrageenan and complete Freund's adjuvant models). Antiallodynic efficacy of BAY 59-3074 (1 mg/kg, p.o.) in the spared nerve injury model was maintained after 2 weeks of daily administration. However, tolerance developed rapidly (within 5 days) for cannabinoid-related side effects, which occur at doses above 1 mg/kg (e.g., hypothermia). Uptitration from 1 to 32 mg/kg p.o. (doubling of daily dose every 4th day) prevented the occurrence of such side effects, whereas antihyperalgesic and antiallodynic efficacy was maintained/increased. No withdrawal symptoms were seen after abrupt withdrawal following 14 daily applications of 1 to 10 mg/kg p.o. It is concluded that BAY 59-3074 may offer a valuable therapeutic approach to treat diverse chronic pain conditions.

Address correspondence to: Dr. Jean De Vry, Biomedical Research, Grünenthal GmbH, Zieglerstrae 6, 52078 Aachen, Germany. E-mail: jean.devry{at}grunenthal.de